Thomas N. Kakuda

机构：Johnson & Johnson (United States) · ORCID：0000-0001-6857-2572

发表论文 154 篇 · 总被引 4411 次 · h-index 35

代表论文

• Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial (2023 · ˜The œLancet. Gastroenterology & hepatology · 被引 82)
• JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2 (2024 · Journal of Hepatology · 被引 52)
• Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study (2022 · Journal of Hepatology · 被引 22)
• Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations (2025 · Nucleic Acids Research · 被引 21)
• Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model (2025 · New England Journal of Medicine · 被引 17)
• JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B (2022 · Antiviral Therapy · 被引 16)